Supplemental Material

 Table S1: Characteristics of the identified studies of trimethylamine N-oxide (TMAO) levels and the prevalent cardiovascular diseases (cross-sectional studies)

Source	Country	Study Population	Age, mean, y	TMAO, mean or median, μM	Men, %	Total N	Outcomes assessed	Events, N
Wang Z, et al. $(2011)^{1}$	US	GeneBank	63.9	NA	49.3	1020	Coronary artery disease (CAD)	As%,41.0
							Peripheral artery disease (PAD)	As%, 24.5
							Cardiovascular disease (CVD) as indicated by either CAD or PAD	As%, 65.4
							Myocardial infarction (MI)	NA
		BioBank	64.5	NA	48.3	856	CAD	As%, 43.7
							PAD	As%, 21.5
							CVD as indicated by either CAD or PAD	As%, 65.2
							MI	NA
Mente A, et al. (2015) <sup>2</sup>	Canada	Study of Health Assessment and Risk in Ethnic Groups [SHARE] and SHARE and Aboriginal Peoples [SHARE-AP]	52.5	1.998	64.9	271	CVD	99

Source	Outcome	Comparison	Model	Relative risk (95% CI)	Adjustment for Covariates
Wang Z, et al. (2011) GeneBank <sup>1</sup>	Coronary artery disease (CAD)	Highest quartile vs. lowest	Multivariate	2.59 (1.88, 3.55)	Age, sex, smoking, diabetes, medication use, hypertension, lipids, C-reactive protein (CRP), and estimated creatinine clearance
	Peripheral artery disease (PAD)	Same as the above	Multivariate	3.43 (2.26, 5.21)	Same as the above
	CAD + PAD	Same as the above	Multivariate	4.03 (2.54, 6.40)	Same as the above
	Cardiovascular disease (CVD)	Same as the above	Multivariate	2.54 (1.86, 3.47)	Same as the above
	Myocardial infarction (MI)	Same as the above	Multivariate	1.47 (0.90, 2.40)	Same as the above
Wang Z, et al. (2011) BioBank <sup>1</sup>	CAD	Highest quartile vs. lowest	Multivariate	3.08 (1.94, 4.88)	Same as the above
	PAD	Same as the above	Multivariate	3.75 (2.00, 7.03)	Same as the above
	CAD + PAD	Same as the above	Multivariate	4.00 (2.04, 7.82)	Same as the above
	CVD	Same as the above	Multivariate	3.08 (1.96, 4.86)	Same as the above
	MI	Same as the above	Multivariate	2.11 (1.33, 3.34)	Same as the above
Mente A, et al. $(2015)^2$	CVD	Highest quintile ( $\geq 2.5 \mu M$ ) vs. lowest	Crude	3.28 (1.37, 7.87)	Crude
			Multivariate	3.17 (1.05, 9.51)	Age, sex, body mass index (BMI), smoking and energy intake
			Multivariate	9.33 (1.88, 46.37)	Age, sex, BMI, smoking, energy intake, diabetes, meat intake, fish intake, and dietary cholesterol

**Table S2:** Relative risks (RRs) of major cardiovascular events according to trimethylamine N-oxide (TMAO) levels in cross-sectional studies

**Figure S1:** Pooled relative risks of high trimethylamine N-oxide (TMAO) levels for the risk of major adverse clinical events/death (A) and all-cause mortality (B) using 18 data points.<sup>3-18</sup>

Idyname		% Weigł
ng WH, et al. (2013) Death, MI/stroke (SRef. 3)	1.43 (1.05, 1.94)	
ver M, et al. (2014) Admission for HF, Non-DM (4)		
ver M, et al. (2014) All CVD events, DM (4)		
ng WH, et al. (2014) All-cause mortality (5) Iysen GA, et al. (2015) Cardiovascular death/hospitalization (6)	1.85 (1.14, 3.00) 0.92 (0.40, 2.11)	
pseid M, et al. (2015) All-cause mortality/heart transplantation (7)	1.76 (0.93, 3.33)	
ng WH, et al. (2015) All-cause motality, CKD (8)	1.93 (1.13, 3.29)	
ng WH, et al. (2015) All-cause mortality, NonCKD (8)	1.47 (1.02, 2.12)	
zuki T, et al. (2016) Death/rehospitalisation for HF (9)	2.12 (1.54, 2.92)	
ssailidis C, et al. (2016) All-cause mortality (10)	4.32 (1.32, 14.17	
ubbs JR, et al. (2016) All-cause mortality (11)	1.95 (0.91, 4.17)	
m RB, et al. (2016) Ischemic cardiovascular events (12)	1.37 (0.91, 2.06)	
enthong V, et al. (2016) All-cause mortality (13)	1.71 (1.12, 2.62)	6.96
afi T, et al. (2017) Cardiac death, White (14)	1.78 (1.12, 2.82)	5.97
binson-Cohen C, et al. (2016) All-cause mortality (15)	1.25 (0.48, 3.27)	1.38
tiger M, et al. (2016) All-cause mortality (16)	1.90 (1.10, 3.29)	4.22
enthong V, et al (2016) All-cause mortality (17)	1.59 (1.03, 2.45)	6.78
ng WH et al. (2017) MACE (18)	1.94 (1.23, 3.05)	6.17
rerall (I-squared = 0.0%, p = 0.851)	1.70 (1.52, 1.91)	100.
3	.5 1 1.5 2 2.5 RR (95% CI)	%
<b>}</b> Studyname	ES (95% CI)	
	RR (95% CI)	Wei
Studyname	RR (95% CI) ES (95% CI)	Wei 6.19
ever M, et al. (2014) All-cause mortality, Non-DM (4)	RR (95% CI) ES (95% CI) 2.70 (1.56, 4.68)	Wei 6.19 2.15
ever M, et al. (2014) All-cause mortality, Non-DM (4) ever M, et al. (2014) All-cause mortality, DM (4) ang WH, et al. (2014) All-cause mortality (5)	RR (95% CI) ES (95% CI) 2.70 (1.56, 4.68) 2.70 (1.06, 6.86)	Wei 6.19 2.15 7.98
itudyname ever M, et al. (2014) All-cause mortality, Non-DM (4) ever M, et al. (2014) All-cause mortality, DM (4) ang WH, et al. (2014) All-cause mortality (5) aysen GA, et al. (2015) All-cause mortality (6)	RR (95% CI) ES (95% CI) 2.70 (1.56, 4.68) 2.70 (1.06, 6.86) 1.85 (1.14, 3.00)	Wei 6.19 2.15 7.98 6.68
ever M, et al. (2014) All-cause mortality, Non-DM (4) ever M, et al. (2014) All-cause mortality, DM (4) ang WH, et al. (2014) All-cause mortality (5) (aysen GA, et al. (2015) All-cause mortality (6) ang WH, et al. (2015) All-cause mortality, CKD (8)	RR (95% CI) ES (95% CI) 2.70 (1.56, 4.68) 2.70 (1.06, 6.86) 1.85 (1.14, 3.00) 1.14 (0.67, 1.93)	Wei 6.19 2.15 7.98 6.68 6.54
ever M, et al. (2014) All-cause mortality, Non-DM (4) ever M, et al. (2014) All-cause mortality, DM (4) ang WH, et al. (2014) All-cause mortality (5) aysen GA, et al. (2015) All-cause mortality (6) ang WH, et al. (2015) All-cause mortality, CKD (8) ang WH, et al. (2015) All-cause mortality, NonCKD (8)	RR (95% CI) ES (95% C) 2.70 (1.56, 4.68) 2.70 (1.06, 6.86) 1.85 (1.14, 3.00) 1.14 (0.67, 1.93) 1.93 (1.13, 3.29) 1.47 (1.02, 2.12)	Wei 6.19 2.15 7.98 6.68 6.54 13.9
ever M, et al. (2014) All-cause mortality, Non-DM (4) ever M, et al. (2014) All-cause mortality, DM (4)	RR (95% CI) ES (95% C) 2.70 (1.56, 4.68) 2.70 (1.06, 6.86) 1.85 (1.14, 3.00) 1.14 (0.67, 1.93) 1.93 (1.13, 3.29) 1.47 (1.02, 2.12)	Wei 6.19 2.15 7.98 6.68 6.54 13.9 1.32
ever M, et al. (2014) All-cause mortality, Non-DM (4) ever M, et al. (2014) All-cause mortality, DM (4) ang WH, et al. (2014) All-cause mortality (5) (aysen GA, et al. (2015) All-cause mortality (6) ang WH, et al. (2015) All-cause mortality, CKD (8) ang WH, et al. (2015) All-cause mortality, NonCKD (8) tissailidis C, et al. (2016) All-cause mortality (10)	RR (95% CI) ES (95% C) 2.70 (1.56, 4.68) 2.70 (1.56, 4.68) 1.85 (1.14, 3.00) 1.14 (0.67, 1.93) 1.93 (1.13, 3.29) 1.47 (1.02, 2.12) 4.32 (1.32, 14.17)	Wei 6.19 2.15 7.98 6.68 6.54 13.9 1.32 3.22
ever M, et al. (2014) All-cause mortality, Non-DM (4) ever M, et al. (2014) All-cause mortality, DM (4) ang WH, et al. (2014) All-cause mortality (5) aysen GA, et al. (2015) All-cause mortality (6) ang WH, et al. (2015) All-cause mortality, CKD (8) ang WH, et al. (2015) All-cause mortality, NonCKD (8) tissailidis C, et al. (2016) All-cause mortality (10) tubbs JR, et al. (2016) All-cause mortality (11) enthong V, et al. (2016) All-cause mortality (13)	RR (95% CI) ES (95% C) 2.70 (1.56, 4.68) 2.70 (1.06, 6.86) 1.85 (1.14, 3.00) 1.14 (0.67, 1.93) 1.93 (1.13, 3.29) 1.47 (1.02, 2.12) 4.32 (1.32, 14.17) 1.95 (0.91, 4.17)	Wei 6.19 2.15 7.98 6.68 6.54 13.9 1.32 3.22 10.2
ever M, et al. (2014) All-cause mortality, Non-DM (4) ever M, et al. (2014) All-cause mortality, DM (4) ang WH, et al. (2014) All-cause mortality (5) (aysen GA, et al. (2015) All-cause mortality (6) ang WH, et al. (2015) All-cause mortality, CKD (8) ang WH, et al. (2015) All-cause mortality, NonCKD (8) tissailidis C, et al. (2016) All-cause mortality (10) stubbs JR, et al. (2016) All-cause mortality (11)	RR (95% CI) ES (95% C) 2.70 (1.56, 4.68) 2.70 (1.56, 4.68) 2.70 (1.06, 6.86) 1.85 (1.14, 3.00) 1.14 (0.67, 1.93) 1.93 (1.13, 3.29) 1.47 (1.02, 2.12) 4.32 (1.32, 14.17) 1.95 (0.91, 4.17) 1.71 (1.12, 2.62)	Wei 6.19 2.15 7.98 6.68 6.54 13.9 1.32 3.22 10.2 13.2
ever M, et al. (2014) All-cause mortality, Non-DM (4) ever M, et al. (2014) All-cause mortality, DM (4) ang WH, et al. (2014) All-cause mortality (5) faysen GA, et al. (2015) All-cause mortality (6) ang WH, et al. (2015) All-cause mortality, CKD (8) ang WH, et al. (2015) All-cause mortality, NonCKD (8) dissailidis C, et al. (2016) All-cause mortality (10) stubbs JR, et al. (2016) All-cause mortality (11) senthong V, et al. (2016) All-cause mortality (13) shafi T, et al. (2017) All-cause mortality, White (14) tobinson-Cohen C, et al. (2016) All-cause mortality (15)	RR (95% CI) ES (95% C) 2.70 (1.56, 4.68) 2.70 (1.06, 6.86) 1.85 (1.14, 3.00) 1.14 (0.67, 1.93) 1.93 (1.13, 3.29) 1.47 (1.02, 2.12) 4.32 (1.32, 14.17) 1.95 (0.91, 4.17) 1.71 (1.12, 2.62) 1.50 (1.03, 2.18)	Wei 6.19 2.15 7.98 6.68 6.54 13.9 1.32 3.22 10.2 13.2 2.02
ever M, et al. (2014) All-cause mortality, Non-DM (4) ever M, et al. (2014) All-cause mortality, DM (4) ang WH, et al. (2014) All-cause mortality (5) (aysen GA, et al. (2015) All-cause mortality (6) ang WH, et al. (2015) All-cause mortality, CKD (8) (ang WH, et al. (2015) All-cause mortality, NonCKD (8) tissailidis C, et al. (2016) All-cause mortality (10) (tubbs JR, et al. (2016) All-cause mortality (11) (tubbs JR, et al. (2016) All-cause mortality (13) (that T, et al. (2017) All-cause mortality, White (14)	RR (95% CI) ES (95% C) 2.70 (1.56, 4.68) 2.70 (1.06, 6.86) 1.85 (1.14, 3.00) 1.14 (0.67, 1.93) 1.93 (1.13, 3.29) 1.47 (1.02, 2.12) 4.32 (1.32, 14.17) 1.95 (0.91, 4.17) 1.71 (1.12, 2.62) 1.50 (1.03, 2.18) 1.25 (0.48, 3.27)	% Wei 6.19 2.15 7.98 6.68 6.54 13.9 1.32 3.22 10.2 13.2 2.02 6.19 9.95
ever M, et al. (2014) All-cause mortality, Non-DM (4) ever M, et al. (2014) All-cause mortality, DM (4) ang WH, et al. (2014) All-cause mortality (5) (aysen GA, et al. (2015) All-cause mortality (6) ang WH, et al. (2015) All-cause mortality, CKD (8) (ang WH, et al. (2015) All-cause mortality, NonCKD (8) fissailidis C, et al. (2016) All-cause mortality (10) (tubbs JR, et al. (2016) All-cause mortality (11) (einthong V, et al. (2016) All-cause mortality (13) (thafi T, et al. (2017) All-cause mortality, White (14) (tobinson-Cohen C, et al. (2016) All-cause mortality (15) (titiger M, et al. (2016) All-cause mortality (16)	RR (95% CI) ES (95% C) 2.70 (1.56, 4.68) 2.70 (1.06, 6.86) 1.85 (1.14, 3.00) 1.14 (0.67, 1.93) 1.93 (1.13, 3.29) 1.47 (1.02, 2.12) 4.32 (1.32, 14.17) 1.95 (0.91, 4.17) 1.95 (0.91, 4.17) 1.71 (1.12, 2.62) 1.50 (1.03, 2.18) 1.25 (0.48, 3.27) 1.90 (1.10, 3.29)	Wei 6.19 2.15 7.98 6.68 6.54 13.9 1.32 3.22 10.2 13.2 2.02 6.19
ever M, et al. (2014) All-cause mortality, Non-DM (4) ever M, et al. (2014) All-cause mortality, DM (4) ang WH, et al. (2014) All-cause mortality (5) (aysen GA, et al. (2015) All-cause mortality (6) ang WH, et al. (2015) All-cause mortality, CKD (8) (ang WH, et al. (2015) All-cause mortality, NonCKD (8) dissailidis C, et al. (2016) All-cause mortality (10) dissailidis C, et al. (2016) All-cause mortality (10) distubs JR, et al. (2016) All-cause mortality (11) eenthong V, et al. (2016) All-cause mortality (13) dishafi T, et al. (2017) All-cause mortality, White (14) dobinson-Cohen C, et al. (2016) All-cause mortality (15) oftiger M, et al. (2016) All-cause mortality (16) eenthong V, et al (2016) All-cause mortality (17)	RR (95% CI) ES (95% C) 2.70 (1.56, 4.68) 2.70 (1.06, 6.86) 1.85 (1.14, 3.00) 1.14 (0.67, 1.93) 1.93 (1.13, 3.29) 1.47 (1.02, 2.12) 4.32 (1.32, 14.17) 1.95 (0.91, 4.17) 1.95 (0.91, 4.17) 1.95 (0.91, 4.17) 1.90 (1.10, 3.29) 1.59 (1.03, 2.48) 1.59 (1.03, 2.45) 1.85 (1.21, 2.83)	Wei 6.19 2.15 7.98 6.68 6.54 13.9 1.32 3.22 10.2 13.2 2.02 6.19 9.95
ever M, et al. (2014) All-cause mortality, Non-DM (4) ever M, et al. (2014) All-cause mortality, DM (4) ang WH, et al. (2014) All-cause mortality (5) (aysen GA, et al. (2015) All-cause mortality (6) ang WH, et al. (2015) All-cause mortality, CKD (8) ang WH, et al. (2015) All-cause mortality, NonCKD (8) lissailidis C, et al. (2016) All-cause mortality (10) tubbs JR, et al. (2016) All-cause mortality (11) tenthong V, et al. (2016) All-cause mortality (13) ihafi T, et al. (2017) All-cause mortality (13) ihafi T, et al. (2016) All-cause mortality (15) enthong V, et al. (2016) All-cause mortality (16) tenthong V, et al. (2016) All-cause mortality (17) ang WH et al. (2017) All-cause mortality (18)	RR (95% CI) ES (95% C) 2.70 (1.56, 4.68) 2.70 (1.06, 6.86) 1.85 (1.14, 3.00) 1.14 (0.67, 1.93) 1.93 (1.13, 3.29) 1.47 (1.02, 2.12) 4.32 (1.32, 14.17) 1.95 (0.91, 4.17) 1.71 (1.12, 2.62) 1.50 (1.03, 2.18) 1.25 (0.48, 3.27) 1.90 (1.10, 3.29) 1.59 (1.03, 2.45)	Wei 6.19 2.15 7.98 6.68 6.54 1.32 1.32 2.02 6.19 9.95 10.2

Dashed lines represent the overall effect, and gray boxes represent weight. SRef, Supplemental references; DM, diabetes; CKD, chronic kidney disease; HF, heart failure.

## **Supplemental References**

- 1 Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* 2011; 472: 57-63.
- 2 Mente A, Chalcraft K, Ak H, Davis AD, Lonn E, Miller R, Potter MA, Yusuf S, Anand SS, McQueen MJ. The Relationship Between Trimethylamine-N-Oxide and Prevalent Cardiovascular Disease in a Multiethnic Population Living in Canada. *Can J Cardiol* 2015; 31: 1189-1194.
- 3 Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. *N Engl J Med* 2013; 368: 1575-1584.
- 4 Lever M, George PM, Slow S, Bellamy D, Young JM, Ho M, McEntyre CJ, Elmslie JL, Atkinson W, Molyneux SL, Troughton RW, Frampton CM, Richards AM, Chambers ST. Betaine and Trimethylamine-N-Oxide as Predictors of Cardiovascular Outcomes Show Different Patterns in Diabetes Mellitus: An Observational Study. *PLoS One* 2014; 9: e114969.
- 5 Tang WH, Wang Z, Fan Y, Levison B, Hazen JE, Donahue LM, Wu Y, Hazen SL. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. *J Am Coll Cardiol* 2014; 64: 1908-1914.
- 6 Kaysen GA, Johansen KL, Chertow GM, Dalrymple LS, Kornak J, Grimes B, Dwyer T, Chassy AW, Fiehn O. Associations of Trimethylamine N-Oxide With Nutritional and Inflammatory Biomarkers and Cardiovascular Outcomes in Patients New to Dialysis. *J Ren Nutr* 2015; 25: 351-356.
- 7 Troseid M, Ueland T, Hov JR, Svardal A, Gregersen I, Dahl CP, Aakhus S, Gude E, Bjorndal B, Halvorsen B, Karlsen TH, Aukrust P, Gullestad L, Berge RK, Yndestad A. Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity

and survival of patients with chronic heart failure. J Intern Med 2015; 277: 717-726.

- 8 Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, Li XS, Levison BS, Hazen SL. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. *Circ Res* 2015; 116: 448-455.
- 9 Suzuki T, Heaney LM, Bhandari SS, Jones DJ, Ng LL. Trimethylamine N-oxide and prognosis in acute heart failure. *Heart* 2016; 102: 841-848.
- 10 Missailidis C, Hallqvist J, Qureshi AR, Barany P, Heimburger O, Lindholm B, Stenvinkel P, Bergman P. Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease. *PLoS One* 2016; 11: e0141738.
- 11 Stubbs JR, House JA, Ocque AJ, Zhang S, Johnson C, Kimber C, Schmidt K, Gupta A, Wetmore JB, Nolin TD, Spertus JA, Yu AS. Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. J Am Soc Nephrol 2016; 27: 305-313.
- 12 Kim RB, Morse BL, Djurdjev O, Tang M, Muirhead N, Barrett B, Holmes DT, Madore F, Clase CM, Rigatto C, Levin A, Can PI. Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events. *Kidney Int* 2016; 89: 1144-1152.
- 13 Senthong V, Wang Z, Li XS, Fan Y, Wu Y, Tang WH, Hazen SL. Intestinal Microbiota-Generated Metabolite Trimethylamine-N-Oxide and 5-Year Mortality Risk in Stable Coronary Artery Disease: The Contributory Role of Intestinal Microbiota in a COURAGE-Like Patient Cohort. J Am Heart Assoc 2016; 5(6). pii: e002816. doi: 10.1161/JAHA.115.002816.
- Shafi T, Powe NR, Meyer TW, Hwang S, Hai X, Melamed ML, Banerjee T, Coresh J, Hostetter TH. Trimethylamine N-Oxide and Cardiovascular Events in Hemodialysis Patients. *J Am Soc Nephrol* 2017; 28: 321-331.
- 15 Robinson-Cohen C, Newitt R, Shen DD, Rettie AE, Kestenbaum BR, Himmelfarb J, Yeung CK.

Association of FMO3 Variants and Trimethylamine N-Oxide Concentration, Disease Progression, and Mortality in CKD Patients. *PLoS One* 2016; 11: e0161074.

- 16 Ottiger M, Nickler M, Steuer C, Odermatt J, Huber A, Christ-Crain M, Henzen C, Hoess C, Thomann R, Zimmerli W, Mueller B, Schuetz P. Trimethylamine-N-oxide (TMAO) predicts fatal outcomes in community-acquired pneumonia patients without evident coronary artery disease. *Eur J Intern Med* 2016; 36: 67-73.
- 17 Senthong V, Wang Z, Fan Y, Wu Y, Hazen SL, Tang WH. Trimethylamine N-Oxide and Mortality Risk in Patients With Peripheral Artery Disease. J Am Heart Assoc 2016; 5(10). pii: e004237.
- 18 Tang WH, Wang Z, Li XS, Fan Y, Li DS, Wu Y, Hazen SL. Increased Trimethylamine N-Oxide Portends High Mortality Risk Independent of Glycemic Control in Patients with Type 2 Diabetes Mellitus. *Clin Chem* 2017; 63: 297-306.